Answers are grounded in this paper and cite their sources.
Cirrhosis represents the body's wound healing response to liver injury, is analogous to wound healing in other parenchymal organs,1 and is associated with portal hypertension. Indeed, portal hypertension represents the major complication of cirrhosis and is tightly linked to clinical outcomes in patients with cirrhosis. In fact, of all the clinical variables used to predict outcomes in patients with cirrhosis, the hepatic venous pressure gradient (HVPG) is arguably the best. However, the measurement of HVPG is considered to be an invasive procedure and requires specific expertise.2 The pathophysiology of portal hypertension is complex (Figure 1),3 but it is important to emphasize that an early and prominent feature of all forms of chronic parenchymal liver injury is the development of an endotheliopathy—that is an alteration of normal sinusoidal function—early in the disease process. The major cells in the hepatic sinusoid include sinusoidal endothelial cells (SECs) and stellate cells, each of which appears to play a role in the regulation of sinusoidal blood flow.4-6 Stellate cells possess extensive cytoplasmic processes that encircle many if not all SECs,7, 8 suggesting that stellate cells function as liver-specific pericytes, a cell type that controls capillary blood flow in a wide variety of tissues.9, 10 Further, the close anatomic relationship of SECs to stellate cells suggests a (functional) paracrine relationship between the two cell types. Most forms of liver injury, particularly early in the disease process, result in “sinusoidal” portal hypertension—caused by changes in the sinusoid that lead to increased intrahepatic resistance.3, 11 A resistance “balance” revolves around vasoconstrictor peptides and vasorelaxing agents, as well as altered function of stellate cells (which develop a contractile phenotype) and SECs. The lack of production of the potent vasodilator nitric oxide (NO) by SECs is perhaps the most remarkable element in endotheliopathy and many have suggested that this is a key harbinger of the abnormal SEC phenotype. Later in the disease, after changes in intrahepatic resistance have occurred, remodeling of the mesenteric vasculature occurs leading to a high flow state. Together, these derangements, in the context of ongoing hepatic fibrosis that undoubtedly leads to further increases in intrahepatic resistance, result in the portal hypertensive disease state. Currently, there are many critical unmet needs in the field of portal hypertension (Table 1)—and addressing these will be a major focus of Portal Hypertension & Cirrhosis. First, much more research is required both at the bench, as well as at the bedside. It will be critical to continue discovery research and to better understand the pathophysiologic basis of the underlying endotheliopathy in liver disease and portal hypertension. In addition, the natural history of portal hypertension in patients is poorly understood—especially in early disease. Further, the idea that an absolute degree of portal hypertension (“clinically significant portal hypertension” [CSPH]) is necessary to lead to clinical complications, has undercome some degree of scrutiny, and it is not clear that CSPH is sufficient to cause complications. One of the most critical areas for research will be in the area of development and perfection of noninvasive assessments for portal hypertension.12 Currently, some evidence suggests that blood tests of fibrosis (i.e., Fib-4, APRI, etc.) or perhaps imaging (vibration controlled transient elastography, ultrasound-directed transient elastography, or magnetic resonance elastography) may be acceptable modalities to assess the severity of portal hypertension (and perhaps the presence of esophageal varices). In addition, more sensitive and specific techniques are required, whether they are blood based or imaging based. The lack of reliable noninvasive assessments for portal hypertension will undoubtedly limit the development of novel treatments. Finally, new treatments for portal hypertension are required. Currently, the only effective pharmacological treatment for portal hypertension is (nonselective) beta-blockade. New pharmacologic treatments must be identified, tested, and brought to the clinic. Finally, it is clear that the management of patients with cirrhosis and portal hypertension requires great expertise. This expertise includes practitioners of all forms including hepatologists, gastroenterologists, imaging specialists, interventional radiologists, and surgeons.13 Ideally, all patients with cirrhosis and portal hypertension should be managed in centers with expert representatives in all these fields. However, given the explosion in new cirrhosis diagnoses, largely driven by the exploding nonalcoholic fatty liver disease epidemic now and for the foreseeable future, it will likely be impossible for all patients with cirrhosis and portal hypertension to be cared for by experts. Nonetheless, efforts should be made to educate and engage the broader medical community about the importance of cirrhosis and portal hypertension and, moreover, best practices in management. One example of this effort is the recent development of “A Community of Portal Hypertension,”13 emphasizing the importance of a multidisciplinary team-oriented approach to research and management in portal hypertension. It is with such efforts that the care and outcomes of patients with cirrhosis and portal hypertension will be improved and we hope that Portal Hypertension & Cirrhosis plays a leading role in this effort. It is with great enthusiasm that Portal Hypertension & Cirrhosis will be launched. Through a collaboration of the Chinese Medical Association, Wiley, and the Chinese Portal Hypertension Alliance (CHESS), this journal will create a platform for communication and dissemination of research and patient care in the field of portal hypertension. The author conceived of the work, and wrote the manuscript in its entirety. None. This work was supported, in part, by the National Institute of Diabetes and Digestive and Kidney Disease (grant number: P30 DK123704) and the National Institute of General Medical Sciences (grant number: P20 GM 130457). This manuscript has not been published elsewhere and is not under consideration for publication elsewhere. The author has no conflict of interest related to this work to disclose.
No takes yet. Share an insight, caveat, or question.
Don C. Rockey (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: